[{"orgOrder":0,"company":"ExpreS2ion Biotechnologies","sponsor":"The EU Horizon 2020 Consortium","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"DENMARK","productType":"Vaccine","year":"2020","type":"Funding","leadProduct":"COVID-19 Vaccine","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"ExpreS2ion Biotechnologies","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"ExpreS2ion Biotechnologies \/ The EU Horizon 2020 Consortium","highestDevelopmentStatusID":"1","companyTruncated":"ExpreS2ion Biotechnologies \/ The EU Horizon 2020 Consortium"}]

Find Clinical Drug Pipeline Developments & Deals by ExpreS2ion Biotechnologies

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Pharmex
                          Not Confirmed
                          Pharmex
                          Not Confirmed

                          Details : The aim of the grant is to support the consortium in development of a COVID-19 vaccine candidate, including performing a Phase I/IIa clinical trial.

                          Product Name : Undisclosed

                          Product Type : Vaccine

                          Upfront Cash : Undisclosed

                          June 03, 2020

                          Lead Product(s) : COVID-19 Vaccine

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Undisclosed

                          Sponsor : The EU Horizon 2020 Consortium

                          Deal Size : $0.9 million

                          Deal Type : Funding

                          blank